CG Oncology, Inc. Common stock Total Liabilities
CG Oncology, Inc. Common stock total liabilities. Based on the latest financial reports, CG Oncology, Inc. Common stock (CGON) has total liabilities worth $38.99 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CG Oncology, Inc. Common stock (CGON) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CG Oncology, Inc. Common stock (2021–2025)
Total liabilities of CG Oncology, Inc. Common stock from 2021 to 2025. This chart illustrates how CG Oncology, Inc. Common stock's total liabilities have evolved over time, based on quarterly financial data.
CG Oncology, Inc. Common stock Competitors by Total Liabilities
The table below lists competitors of CG Oncology, Inc. Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Koninklijke Vopak NV
AS:VPK
|
Netherlands | €3.68 Billion |
|
Perseus Mining Ltd
AU:PRU
|
Australia | AU$465.51 Million |
|
Guangdong Fenghua Advanced Technology Holding Co Ltd
SHE:000636
|
China | CN¥4.22 Billion |
|
Puya Semiconductor Shanghai Co Ltd
SHG:688766
|
China | CN¥2.47 Billion |
|
Yunnan Tin Co Ltd
SHE:000960
|
China | CN¥15.59 Billion |
|
NEXANS ADR EO 1
F:NXS0
|
Germany | €6.02 Billion |
|
3Peak Inc
SHG:688536
|
China | CN¥808.95 Million |
|
TMBThanachart Bank Public Company Limited
F:NVPJ
|
Germany | €1.46 Trillion |
Liability Composition Analysis (2021–2025)
This chart breaks down CG Oncology, Inc. Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CG Oncology, Inc. Common stock balance sheet assets.
Liquidity & Leverage Metrics
CG Oncology, Inc. Common stock Total Liabilities Ratios Explained
CG Oncology, Inc. Common stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CG Oncology, Inc. Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CG Oncology, Inc. Common stock (2021–2025)
The table below shows the annual total liabilities of CG Oncology, Inc. Common stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $38.99 Million | +82.03% |
| 2024-12-31 | $21.42 Million | +47.61% |
| 2023-12-31 | $14.51 Million | -35.71% |
| 2022-12-31 | $22.57 Million | +22.40% |
| 2021-12-31 | $18.44 Million | -- |
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more